Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors
Yemarshet K. Gebreyohannes(KU Leuven), Patrick Schöffski(KU Leuven)
Cited by 77
Related Papers
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer
|Breast Cancer Research|2018|93
Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different <i>KIT</i> Mutations
|Molecular Cancer Therapeutics|2016|32
Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors
|Clinical Sarcoma Research|2014|26
Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma
|International Journal of Molecular Sciences|2022|19